Pharmaceuticals

HEPALINK

HEPALINK released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue HKD 1.509 B, actual EPS HKD 0.1448

HEPALINK FY2026 Q1 Earnings Release Scheduled for April 29 After-Market BJT

HEPALINK released FY2025 Annual Earnings on March 30 After-Market (BJT), Actual Revenue HKD 5.988 B (Forecast HKD 5.911 B), Actual EPS HKD 0.2603 (Forecast HKD 0.2557)

HEPALINK released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue HKD 1.428 B (forecast HKD 1.283 B), actual EPS HKD -0.1546 (forecast HKD -0.1668)

HEPALINK to release FY2025 earnings on March 30 After-Market (BJT), forecast revenue HKD 5.982 B, EPS HKD 0.2588

HEPALINK released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue HKD 4.556 B, actual EPS HKD 0.4103

HEPALINK released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue HKD 1.505 B (forecast HKD 1.539 B), actual EPS HKD 0.0981 (forecast HKD 0.0983)

HEPALINK to Release FY2025 Q3 Earnings on October 30 After-Market (BJT), Forecast Revenue HKD 1.539 B, EPS HKD 0.0983

HEPALINK released FY2025 Semi-Annual Earnings on August 29 After-Market (BJT), actual revenue HKD 3.05 B, actual EPS HKD 0.3112

HEPALINK released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue HKD 1.558 B (forecast HKD 1.4 B), actual EPS HKD 0.1979 (forecast HKD 0.0218)

HEPALINK to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

H1710 Enters Clinical Assessment Stage

H1710, a New Drug Developed by Hepalink, Completes First Patient Dosing in Phase I Clinical Trial

Hybrivia Pharmaceuticals Submits New Trademark Applications

Huapu's Enoxaparin Sodium Injection Receives EMA Approval for New Manufacturer

Hepalink Announces Final Dividend for 2024

Hepalink Receives EMA Approval for New Production of Enoxaparin Sodium Injection

Hepalink Announces Final Dividend Distribution for July 22, 2025

HEPALINK released FY2025 Q1 earnings on April 24 After-Market (BJT), actual revenue HKD 1.493 B (forecast HKD 1.191 B), actual EPS HKD 0.1142 (forecast HKD 0.0954)

Huipu Releases 2025 Q1 Financial Report

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.05.27, Cash dividend 0.164 HKD

09989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has filed its unaudited financial results for Q1 2026, with full board approval, emphasizing regulatory compliance and transparency. The board confirmed all directors attended the meeting on April 29, 2026, where the report was approved. The disclosure aligns with Hong Kong securities regulations and highlights management's responsibility for data integrity. The latest analyst rating for the stock (HK:9989) is a Sell, with a price target of HK$4.31, and the company has a market cap of HK$16.62B.

Tip Ranks

Hepalink

Hepalink Files Unaudited First-Quarter 2026 Report With Full Board Approval

002399

HEPALINK announced its full-year results for the year ended December last year, with a revenue of RMB 5.438 billion, an increase of 3.4% year-on-year. The net profit was RMB 349 million, a decrease of 46% year-on-year; earnings per share were RMB 0.24. A final dividend of 14.5 cents was declared, compared to 25 cents in the same period last year

AASTOCKS

"Performance" Hepalink's annual net profit of RMB 349 million fell by 46%, with a final dividend of 14.5 cents per share

02643

02650

02268

02076

03360

02858

00565

01860

02096

CAOCAO INC(02643) fell 11.11%, with a trading turnover 182.4 Million HKD, and a year-to-date fell 1.2%. ZHIDA TECH(02650) fell 7.89%, with a trading turnover 8.7 Million HKD, and a year-to-date rose 224.6%. HEPALINK(09989) fell 7.21%, with a trading turnover 22.3 Million HKD, and a year-to-date rose 39.6%.

Top Gainers&Losers

CAOCAO INC

ZHIDA TECH

WUXI XDC

BOSS ZHIPIN-W

FE HORIZON

YIXIN

ART GROUP HOLD

MOBVISTA

SIMCERE PHARMA

Top 10 HK Stock Losers (12.12)

STECH

09698

36Kr learned that the Hang Seng Index opened up 0.06%, while the Hang Seng TECH Index fell 0.11%; the software services, automotive, and pharmaceutical sectors led the gains, with GDS rising over 4%, and Nio, XPeng, and Hepalink rising over 1%; the semiconductor, non-ferrous metals, and media sectors weakened, with SMIC, Northern Mining, and Kuaishou falling over 1%

36Kr

Hang Seng TECH Index

GDS-SW

The Hang Seng Index opened up 0.06%, while the Hang Seng TECH Index fell 0.11%

HEPALINK(09989.HK)

Hepalink Files Unaudited First-Quarter 2026 Report With Full Board Approval

"Performance" Hepalink's annual net profit of RMB 349 million fell by 46%, with a final dividend of 14.5 cents per share

Top 10 HK Stock Losers (12.12)

The Hang Seng Index opened up 0.06%, while the Hang Seng TECH Index fell 0.11%

Trending